{"id":743815,"date":"2013-07-01T16:05:00","date_gmt":"2013-07-01T16:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/"},"modified":"2023-03-22T00:04:36","modified_gmt":"2023-03-22T04:04:36","slug":"fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/","title":{"rendered":"FDA Approves New U.S. Labeling for ISENTRESS\u00ae (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved new labeling for ISENTRESS<sup>\u00ae<\/sup> (raltegravir)<br \/>\n      Film-coated Tablets, Merck\u2019s integrase inhibitor for the treatment of<br \/>\n      HIV-1 infection in adult patients as part of combination HIV therapy.<br \/>\n      The updated prescribing information now includes 240-week results from<br \/>\n      the STARTMRK study, the longest double-blind Phase III non-inferiority<br \/>\n      study evaluating an integrase inhibitor in treatment-na\u00efve adult<br \/>\n      patients with HIV-1 infection. The results show that the regimen<br \/>\n      containing ISENTRESS in combination therapy demonstrated long-term viral<br \/>\n      suppression and a greater immunologic response than the<br \/>\n      efavirenz-containing regimen, as well as a proven, long-term safety and<br \/>\n      tolerability profile through 240 weeks in previously untreated<br \/>\n      (treatment-na\u00efve) adult HIV-1 infected patients.\n    <\/p>\n<p>\n      ISENTRESS is an integrase inhibitor indicated in combination with other<br \/>\n      antiretroviral (ARV) agents for the treatment of HIV-1 infection in<br \/>\n      adults. This indication is based on analyses of plasma HIV-1 RNA levels<br \/>\n      in three double-blind controlled studies of ISENTRESS. Two of these<br \/>\n      studies were conducted in clinically advanced, three-class ARV<br \/>\n      [non-nucleoside reverse transcriptase inhibitor (NNRTI), nucleoside<br \/>\n      reverse transcriptase inhibitor (NRTI), protease inhibitor (PI)]<br \/>\n      treatment-experienced adult patients through 96 weeks and one was<br \/>\n      conducted in treatment-na\u00efve adults through 240 weeks.\n    <\/p>\n<p>\n      The use of other active agents with ISENTRESS (raltegravir) is<br \/>\n      associated with a greater likelihood of treatment response.\n    <\/p>\n<p>\n      Severe, potentially life-threatening and fatal skin reactions have been<br \/>\n      reported with ISENTRESS. Additionally, during the initial phase of<br \/>\n      combination ARV treatment, immune reconstitution syndrome may occur.<br \/>\n      (See Important Selected Safety Information below.)\n    <\/p>\n<p>\n      \u201cAs the care of HIV evolves, ISENTRESS continues to be an important<br \/>\n      treatment option for adult patients with HIV-1,\u201d said J\u00fcrgen Rockstroh,<br \/>\n      M.D., University of Bonn, Bonn-Venusberg, Germany. \u201cThese 240-week<br \/>\n      results are important for physicians to consider when initiating<br \/>\n      treatment with ISENTRESS in combination therapy in treatment-na\u00efve adult<br \/>\n      patients with HIV-1.\u201d\n    <\/p>\n<p>\n      \u201cMerck has been at the forefront of HIV research for close to 30 years.<br \/>\n      The discovery of ISENTRESS and its clinical development program are a<br \/>\n      testament to Merck\u2019s long-term commitment to the research and<br \/>\n      development of medicines for HIV,\u201d said Daria Hazuda, Ph.D., vice<br \/>\n      president of Early Development and Discovery Sciences Research for<br \/>\n      infectious diseases, Merck.\n    <\/p>\n<p>\n      <b>STARTMRK study design<\/b>\n    <\/p>\n<p>\n      STARTMRK was a multi-center, double-blind, randomized,<br \/>\n      active-controlled, Phase III non-inferiority study. In the study,<sup> <\/sup>563<br \/>\n      previously untreated HIV-1 infected adult patients with HIV-1 RNA<br \/>\n      greater than 5,000 copies\/mL received either 400 mg ISENTRESS orally<br \/>\n      twice daily (n=281) or 600 mg efavirenz orally once daily (n=282), each<br \/>\n      in combination with tenofovir\/emtricitabine. The primary endpoint of the<br \/>\n      study was a reduction in HIV-1 viral load to less than 50 copies\/mL at<br \/>\n      week 48. Secondary endpoints included ARV activity, as measured by the<br \/>\n      proportion of patients achieving HIV-1 viral load to less than 50<br \/>\n      copies\/mL at 96 weeks, as well as achieving viral load less than 400<br \/>\n      copies\/mL and change from baseline in CD4 cell count, both measured at<br \/>\n      48 and 96 weeks. Pre-specified exploratory endpoints also included the<br \/>\n      proportion of patients achieving HIV-1 viral load to less than 50<br \/>\n      copies\/mL at 240 weeks, as well as change from baseline in CD4 cell<br \/>\n      count at 240 weeks. Safety was evaluated throughout the study period.<sup><br \/>\n      <\/sup>Merck presented the 240-week STARTMRK study results for the first<br \/>\n      time at AIDS 2012 in Washington, D.C. and the results were subsequently<br \/>\n      published in <i>Journal of Acquired Immune Deficiency Syndromes (JAIDS) <\/i>in<br \/>\n      May 2013.\n    <\/p>\n<p>\n      <b>ISENTRESS (raltegravir) in combination therapy shows long-term<br \/>\n      efficacy in previously untreated adult HIV-1 patients through 240 weeks<\/b>\n    <\/p>\n<p>\n      In the STARTMRK trial, the regimen containing ISENTRESS was non-inferior<br \/>\n      to the regimen containing efavirenz at reducing HIV-1 viral load to<br \/>\n      undetectable levels (less than 50 copies\/mL) at 240 weeks. At the study<br \/>\n      entry, the geometric mean baseline plasma HIV-1 RNA for patients was<br \/>\n      over 100,000 copies\/mL (103,205 copies\/mL for those on a regimen<br \/>\n      containing ISENTRESS (raltegravir) and 106,215 copies\/mL for patients on<br \/>\n      a regimen containing efavirenz). Results for the 240-week analysis<br \/>\n      showed long-term viral suppression (HIV-1 RNA less than 50 copies\/mL)<br \/>\n      for patients on the regimen containing ISENTRESS of 66 percent and 60<br \/>\n      percent for the regimen containing efavirenz [treatment difference of<br \/>\n      6.6 percent of patients with 95 percent confidence interval (CI): -1.4<br \/>\n      percent, 14.5 percent].\n    <\/p>\n<p>\n      The regimen containing ISENTRESS demonstrated a greater immunologic<br \/>\n      response than the regimen containing efavirenz at 240 weeks. Patients on<br \/>\n      the regimen containing ISENTRESS had a mean baseline CD4 cell count of<br \/>\n      219 cells\/mm<sup>3 <\/sup>compared to 217 cells\/mm<sup>3 <\/sup>for<br \/>\n      patients on the regimen containing efavirenz. From study entry to week<br \/>\n      240, patients on the regimen containing ISENTRESS had a mean baseline<br \/>\n      increase in CD4 cell count of 295 cells\/mm<sup>3 <\/sup>versus 236<br \/>\n      cells\/mm<sup>3 <\/sup>for patients on the regimen containing efavirenz.\n    <\/p>\n<p>\n      <b>Safety and tolerability profile for ISENTRESS (raltegravir) through<br \/>\n      240 weeks in STARTMRK<\/b>\n    <\/p>\n<p>\n      In the STARTMRK trial, through 240 weeks, there was a low incidence of<br \/>\n      drug-related adverse reactions of moderate to severe intensity that<br \/>\n      occurred in greater than or equal to 2 percent of patients treated with<br \/>\n      ISENTRESS. These adverse drug reactions as compared to efavirenz were<br \/>\n      insomnia (4 percent, in both arms), headache (4 percent versus 5<br \/>\n      percent), nausea (3 percent versus 4 percent), fatigue (2 percent versus<br \/>\n      3 percent) and dizziness (2 percent versus 6 percent). &#8220;Moderate&#8221;<br \/>\n      reactions were defined as discomfort enough to cause interference with<br \/>\n      usual activity. &#8220;Severe&#8221; reactions were defined as incapacitating with<br \/>\n      inability to work or do usual activity.\n    <\/p>\n<p>\n      Patients on the regimen containing ISENTRESS also demonstrated a lower<br \/>\n      treatment discontinuation rate due to clinical adverse reactions versus<br \/>\n      patients on the regimen containing efavirenz through 240 weeks (5<br \/>\n      percent versus 10 percent, respectively). Additionally, ISENTRESS in<br \/>\n      combination therapy had less effect on lipids [total, low-density<br \/>\n      lipoprotein (LDL), high-density lipoprotein (HDL) cholesterol] and<br \/>\n      triglycerides fasting serum lipids at week 240, as shown in the table<br \/>\n      below.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"15\">\n<p class=\"bwcellpmargin\">\n            <br \/>\n            <b>Lipid Values, Mean Change from Baseline at Week 240<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            \n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Laboratory<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Parameter<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Preferred <\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Term<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\">\n<p class=\"bwcellpmargin\">\n            <b>ISENTRESS 400 mg<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Twice Daily + Emtricitabine (+)<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Tenofovir<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>N = 207<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            \u00a0\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\">\n<p class=\"bwcellpmargin\">\n            <b>Efavirenz 600 mg<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>At Bedtime + Emtricitabine (+) Tenofovir<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>N = 187<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\" rowspan=\"2\">\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Change from<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Baseline at<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Week 240<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Change from<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Baseline at<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Week 240<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Baseline<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Mean<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (mg\/dL)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Week 240<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Mean<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (mg\/dL)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Mean Change<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (mg\/dL)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Baseline<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Mean<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (mg\/dL)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Week 240<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Mean<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (mg\/dL)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Mean Change<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (mg\/dL)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\">\n<p class=\"bwcellpmargin\">\n            <b>LDL- <\/b><br \/><b>Cholesterol*<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>96<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>106<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>10<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>93<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>118<\/b>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>25<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\">\n<p class=\"bwcellpmargin\">\n            <b>HDL- <\/b><br \/><b>Cholesterol*<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>38<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>44<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>6<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>38<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>51<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>13<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc\">\n<p class=\"bwcellpmargin\">\n            <b>Total <\/b><br \/><b>Cholesterol*<\/b>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>159<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>175<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>16<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>157<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>201<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          <b>44<\/b>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Triglyceride*<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            \u00a0\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>128<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>130<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>2<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>141<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>178<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>37<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n<p class=\"bwcellpmargin\">\n            <b>*Fasting (non-random) laboratory tests at Week 240.<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Notes:<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>N = Total number of subjects per treatment group with at least<br \/>\n            one lipid test result available. The analysis is based on all<br \/>\n            available data.<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>If subjects initiated or increased serum lipid-reducing agents,<br \/>\n            the last available lipid values prior to the change in therapy<br \/>\n            were used in the analysis. If the missing data was due to other<br \/>\n            reasons, subjects were censored thereafter for the analysis.<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>At baseline, serum lipid-reducing agents were used in 5% of<br \/>\n            subjects in the group receiving ISENTRESS (raltegravir) and 3% in<br \/>\n            the efavirenz group. Through Week 240, serum lipid-reducing agents<br \/>\n            were used in 9% of subjects in the group receiving ISENTRESS and<br \/>\n            15% in the efavirenz group.<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      <b>Important Selected Safety Information<\/b>\n    <\/p>\n<p>\n      ISENTRESS (raltegravir) does not cure HIV-1 infection or AIDS.\n    <\/p>\n<p>\n      Severe, potentially life-threatening and fatal skin reactions have been<br \/>\n      reported. This includes cases of Stevens-Johnson syndrome,<br \/>\n      hypersensitivity reaction and toxic epidermal necrolysis. Immediately<br \/>\n      discontinue treatment with ISENTRESS and other suspect agents if severe<br \/>\n      hypersensitivity, severe rash, or rash with systemic symptoms or liver<br \/>\n      aminotransferase elevations develop and monitor clinical status,<br \/>\n      including liver aminotransferases closely.\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment.\n    <\/p>\n<p>\n      Co-administration of ISENTRESS with drugs that are strong inducers of<br \/>\n      uridine diphosphate glucuronosyltransferase (UGT1A1) may result in<br \/>\n      reduced plasma concentrations of raltegravir.<b> <\/b>Rifampin, a strong<br \/>\n      inducer of UGT1A1, reduces plasma concentrations of ISENTRESS.<br \/>\n      Therefore, the dose of ISENTRESS for adults should be increased to 800<br \/>\n      mg twice daily during coadministration with rifampin. There are no data<br \/>\n      to guide co-administration of ISENTRESS with rifampin in patients below<br \/>\n      18 years of age.\n    <\/p>\n<p>\n      The most commonly reported (\u22652%) drug-related clinical adverse reactions<br \/>\n      of moderate to severe intensity in treatment-na\u00efve adult patients<br \/>\n      receiving ISENTRESS compared with efavirenz were insomnia (4% vs 4%),<br \/>\n      headache (4% vs 5%), nausea (3% vs 4%), fatigue (2% vs 3%), and<br \/>\n      dizziness (2% vs 6%), respectively. Intensities were defined as follows:<br \/>\n      Moderate (discomfort enough to cause interference with usual activity);<br \/>\n      or Severe (incapacitating with inability to work or do usual activity).\n    <\/p>\n<p>\n      Grade 2 to 4 creatine kinase laboratory abnormalities were observed in<br \/>\n      patients treated with ISENTRESS (raltegravir). Myopathy and<br \/>\n      rhabdomyolysis have been reported. Use with caution in patients at<br \/>\n      increased risk of myopathy or rhabdomyolysis, such as patients receiving<br \/>\n      concomitant medications known to cause these conditions.\n    <\/p>\n<p>\n      Rash occurred more commonly in treatment-experienced subjects receiving<br \/>\n      regimens containing ISENTRESS plus darunavir\/ritonavir, compared to<br \/>\n      subjects receiving ISENTRESS without darunavir\/ritonavir or<br \/>\n      darunavir\/ritonavir without ISENTRESS. However, rash that was considered<br \/>\n      drug-related occurred at similar rates for all three groups. These<br \/>\n      rashes were mild to moderate in severity and did not limit therapy;<br \/>\n      there were no discontinuations due to rash.\n    <\/p>\n<p>\n      ISENTRESS should be used during pregnancy only if the potential benefit<br \/>\n      justifies the potential risk to the fetus. To monitor maternal-fetal<br \/>\n      outcomes of pregnant patients exposed to ISENTRESS, an Antiretroviral<br \/>\n      Pregnancy Registry has been established. Physicians are encouraged to<br \/>\n      register patients by calling 1-800-258-4263.\n    <\/p>\n<p>\n      <b>About ISENTRESS (raltegravir)<\/b>\n    <\/p>\n<p>\n      ISENTRESS is Merck&#8217;s integrase inhibitor for the treatment of HIV-1<br \/>\n      infection in adult patients and pediatric patients ages 2 years and<br \/>\n      older and weighing at least 10 kg as part of combination HIV therapy.<br \/>\n      ISENTRESS works by inhibiting the insertion of HIV-1 DNA into human DNA<br \/>\n      by the integrase enzyme and has demonstrated rapid antiviral activity.<br \/>\n      Inhibiting integrase from performing this essential function limits the<br \/>\n      ability of the virus to replicate and infect new cells. ISENTRESS is now<br \/>\n      approved in combination therapy in more than 76 countries for use in<br \/>\n      treatment-na\u00efve adult patients with HIV-1 and in more than 110 countries<br \/>\n      for use in treatment-experienced adult patients with HIV-1. ISENTRESS,<br \/>\n      in combination therapy, for use in pediatric patients with HIV-1 has<br \/>\n      also been approved for use in 33 countries. Merck is continuing to move<br \/>\n      forward with filings in additional countries around the world.\n    <\/p>\n<p>\n      To assist patients taking ISENTRESS, Merck offers the SUPPORT\u2122 program,<br \/>\n      which provides personal support and patient advocacy regarding<br \/>\n      individual reimbursement issues. For more information about the SUPPORT\u2122<br \/>\n      program, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.merckhelps.com&#038;esheet=50663242&#038;newsitemid=20130701006520&#038;lan=en-US&#038;anchor=www.merckhelps.com&#038;index=1&#038;md5=c518de9b5f5674ee9503ec3e8ba04064\">www.merckhelps.com<\/a><br \/>\n      or call 1-800-850-3430.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50663242&#038;newsitemid=20130701006520&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=2&#038;md5=2aa54210961f256aa5296069e6b1511c\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50663242&#038;newsitemid=20130701006520&#038;lan=en-US&#038;anchor=Twitter&#038;index=3&#038;md5=e71c5976d8765969dbe3521d88cf64b4\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50663242&#038;newsitemid=20130701006520&#038;lan=en-US&#038;anchor=Facebook&#038;index=4&#038;md5=27f7118f3b6c9920193a6b6e26fdd1b2\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50663242&#038;newsitemid=20130701006520&#038;lan=en-US&#038;anchor=YouTube&#038;index=5&#038;md5=6f0968b5467fee2a30c6b6b8e39b8f22\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50663242&#038;newsitemid=20130701006520&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=6&#038;md5=00398ed441ffa5e43fb3f212a9de9460\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ISENTRESS at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&#038;esheet=50663242&#038;newsitemid=20130701006520&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&#038;index=7&#038;md5=18fb8ce62416a93cf26816a14f51cb78\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_pi.pdf<\/b><\/a><b><br \/>\n      and Patient Information for ISENTRESS at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&#038;esheet=50663242&#038;newsitemid=20130701006520&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&#038;index=8&#038;md5=bf59f0a9720663824cc3aa5a3e1ceabd\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_ppi.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>ISENTRESS<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of<br \/>\n      Merck &#038; Co., Inc., Whitehouse Station, N.J., USA<\/b>\n    <\/p>\n<p>\n      <b>INFC-1083968-0000 7\/1<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130701006520r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Caroline Lappetito, 267-305-7639<br \/>Claire        Mulhearn, 908-423-7425<br \/>or<br \/>Investor Contacts:<br \/>Carol        Ferguson, 908-423-4465<br \/>Justin Holko,\u00a0908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved new labeling for ISENTRESS \u00ae (raltegravir) Film-coated Tablets, Merck\u2019s integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. The updated prescribing information now includes 240-week results from the STARTMRK study, the longest double-blind Phase III non-inferiority study evaluating an integrase inhibitor in treatment-na\u00efve adult patients with HIV-1 infection. The results show that the regimen containing ISENTRESS in combination therapy demonstrated long-term viral suppression and a greater immunologic response than the efavirenz-containing regimen, as well as a proven, long-term safety and tolerability profile through 240 weeks in previously untreated (treatment-na\u00efve) adult HIV-1 infected patients. ISENTRESS is an integrase inhibitor indicated in combination with other<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-743815","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves New U.S. Labeling for ISENTRESS\u00ae (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves New U.S. Labeling for ISENTRESS\u00ae (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved new labeling for ISENTRESS \u00ae (raltegravir) Film-coated Tablets, Merck\u2019s integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. The updated prescribing information now includes 240-week results from the STARTMRK study, the longest double-blind Phase III non-inferiority study evaluating an integrase inhibitor in treatment-na\u00efve adult patients with HIV-1 infection. The results show that the regimen containing ISENTRESS in combination therapy demonstrated long-term viral suppression and a greater immunologic response than the efavirenz-containing regimen, as well as a proven, long-term safety and tolerability profile through 240 weeks in previously untreated (treatment-na\u00efve) adult HIV-1 infected patients. ISENTRESS is an integrase inhibitor indicated in combination with other\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:36+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130701006520r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\\\/\",\"name\":\"FDA Approves New U.S. Labeling for ISENTRESS\u00ae (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130701006520r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-07-01T16:05:00+00:00\",\"dateModified\":\"2023-03-22T04:04:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130701006520r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130701006520r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves New U.S. Labeling for ISENTRESS\u00ae (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves New U.S. Labeling for ISENTRESS\u00ae (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves New U.S. Labeling for ISENTRESS\u00ae (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved new labeling for ISENTRESS \u00ae (raltegravir) Film-coated Tablets, Merck\u2019s integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. The updated prescribing information now includes 240-week results from the STARTMRK study, the longest double-blind Phase III non-inferiority study evaluating an integrase inhibitor in treatment-na\u00efve adult patients with HIV-1 infection. The results show that the regimen containing ISENTRESS in combination therapy demonstrated long-term viral suppression and a greater immunologic response than the efavirenz-containing regimen, as well as a proven, long-term safety and tolerability profile through 240 weeks in previously untreated (treatment-na\u00efve) adult HIV-1 infected patients. ISENTRESS is an integrase inhibitor indicated in combination with other","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:36+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130701006520r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/","name":"FDA Approves New U.S. Labeling for ISENTRESS\u00ae (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130701006520r1&sid=sfsite1&distro=nx","datePublished":"2013-07-01T16:05:00+00:00","dateModified":"2023-03-22T04:04:36+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130701006520r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130701006520r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-results-from-startmrk-study-of-isentress-containing-regimen-in-previously-untreated-hiv-1-infected-adult-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Approves New U.S. Labeling for ISENTRESS\u00ae (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"1888807d-71e4-42ef-9d79-406697c51c6f","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743815\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743815"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}